Evolving Paradigms in the Use of Checkpoint Inhibitors for the Management of Patients With Non-Small Cell Lung Cancer
This activity is supported by an educational grant from Merck & Co., Inc.
Click Here to Manage Email Alerts
Overview
Provider Statement
This continuing medical education activity is provided by
Educational Partner
Support Statement
This activity is supported by an educational grant from Merck & Co., Inc.
Activity Description
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases with most patients having advanced disease at the time of diagnosis. Recent updates to guidelines have further defined recommendations for screening, diagnosis, and biomarker testing for the early management of NSCLC. However, the COVID-19 pandemic has complicated the diagnosis and management of NSCLC, potentially impacting clinical outcomes in these patients. Treatment paradigms also continue to rapidly expand for these patients, making optimal selection of individualized therapies challenging. Within this 6-part podcast series, experts in the field will (1) review current recommendations for the optimal management of patients with NSCLC in the shifting clinical setting of the COVID-19 pandemic, (2) assess best practices for testing and interpretation of test results for the management of patients with advanced NSCLC, (3) evaluate first-line treatment options for patients with advanced NSCLC lacking oncogenic driver aberrations, (4) discuss sequencing and combinations of immuno-oncology (IO) regimens for patients with NSCLC who have progressed on first-line treatment, and (5) review the use of checkpoint inhibitors for patients with NSCLC.
Target Audience
The intended audience for this activity is oncologists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with non-small cell lung cancer.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Review current recommendations for optimally managing patients with NSCLC in the shifting clinical setting of the COVID-19 pandemic.
- Consider the patient's perspective to improve care coordination in NSCLC management.
- Review best practices for biomarker testing, test methodologies, and interpretation of test results into the management of patients with advanced NSCLC.
- Define first-line treatment options for patients with advanced NSCLC lacking oncogenic driver aberrations, including those with early-stage disease.
- Describe the latest data regarding sequencing and combination of IO regimens for patients with NSCLC who have progressed on first-line treatment.
- Optimize the use of checkpoint inhibitors for patients with NSCLC.
Activity Co-Chairs
Laurie Carr, MD
Associate Professor of Medicine
Division of Oncology
National Jewish Health
Denver, CO
Jeffrey Kern, MD
Chief, Division of Oncology
Director, Lung Cancer Center
Professor of Medicine
National Jewish Health
Denver, CO
Faculty
Charu Aggarwal, MD, MPH
Leslye M. Heisler Associate Professor of Medicine
Associate Director, Penn Center for Precision Medicine
Associate Director, Penn Center for Cancer Care Innovation (PC3I)
Physician Leader, Airways Malignancies Clinical Research
University of Pennsylvania
Philadelphia, PA
David Ross Camidge, MD, PhD
Professor, Division of Medical Oncology
Joyce Zeff Chair in Lung Cancer Research
University of Colorado Denver School of Medicine
Aurora, CO
Heather Wakelee, MD, FASCO
Professor of Medicine and Chief of the Division of Oncology
Stanford University School of Medicine
Interim Medical Director
Stanford Cancer Center
Deputy Director
Stanford Cancer Institute
President, International Association for the Study of Lung Cancer (IASLC)
Stanford, CA
Patient- and Caregiver-Perspective Participants
Roger White
Ann King White
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Clinical Instructor in Medicine, Thomas Jefferson University Hospital
Physician, Thomas Jefferson University Hospital
University of Pennsylvania Health System
Philadelphia, PA
Zulma Yunt, MD
Assistant Professor of Medicine
Department of Medicine
Medical Director, Office of Professional Education
National Jewish Health
Denver, CO
Accreditation
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
National Jewish Health designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, December 31, 2022, to December 30, 2023.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of 6 of the posttest questions correctly. If a satisfactory score on the posttest is achieved, National Jewish Health will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures
In accordance with the ACCME, National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.
All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.
Relationship information is accurate at the time of content development.
Activity Co-Chairs and Faculty report the following relevant financial relationship(s)
Charu Aggarwal, MD, MPH
Consultant: Genentech; Lilly; Celgene; Merck; AstraZeneca; Blueprint Genetics; Shionogi; Daiichi Sankyo/AstraZeneca; Regeneron/Sanofi; Eisai; BeiGene; Turning Point; Pfizer; Janssen; Boehringer Ingelheim
Investigator: Genentech/Roche; Incyte; Macrogenics; Merck Sharp & Dohme; AstraZeneca/MedImmune
David Ross Camidge, MD, PhD
Consultant: Abbvie
Advisory Board: Abbvie; Anheart; Appolomics; AstraZeneca/Daiichi; BeiGene; Dizal; EMD Serono; Elevation; Hengrui; Hummingbird; Medtronic; Janssen; Mersana Therapeutics; Mirati; Nalo Therapeutics; Onkure; Regeneron; Roche; Sanofi; Takeda; Theseus; Xcovery; Amgen; AstraZeneca; Bio-Thera; Blueprint Genetics; Daiichi Sankyo; Eli Lilly; Helsinn; Kestrel; Nuvalent; Puma; Ribon Therapeutics; Roche/Genentech; Seattle Genetics; Turning Point
Laurie Carr, MD
Consultant: Mersana Therapeutics; Eli Lilly (former)
Advisory Board: Takeda (former)
Jeffrey Kern, MD
No relevant financial relationships to disclose
Heather Wakelee, MD, FASCO
Advisory Board: AstraZeneca; Blueprint Genetics; Genentech/Roche; Merck; Mirati Therapeutics
Investigator: ACEA Biosciences; Arrys Therapeutics; AstraZeneca/MedImmune; BMS; Clovis Oncology; Genentech/Roche; Helsinn; Merck; Novartis; SeaGen; Xcovery
Patient- and Caregiver-Perspective Participants report the following relevant financial relationship(s)
Roger White
No relevant financial relationships to disclose.
Ann King White
No relevant financial relationships to disclose.
Reviewers report the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Zulma Yunt, MD
Speaker: Boehringer Ingelheim
National Jewish Health and Vindico Medical Education Staff:
No relevant financial relationships to disclose.
Signed disclosures are on file at National Jewish Health.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
ADA Disclaimer
In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this Podcast is available upon request. Requests should include the Podcast title and can be emailed to CME@VindicoCME.com. Requests will be honored within 3-5 business days.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.
The material presented at or in any National Jewish Health and Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of National Jewish Health or Vindico Medical Education. Neither National Jewish Health, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CE Questions?
Contact us at proed@njhealth.org